Search Results

You are looking at 1 - 10 of 711 items for :

  • "survival rates" x
  • Refine by Access: All x
Clear All
Full access

Prevalence of Breast Cancer Survivors Among Canadian Women

Amy A. Kirkham and Katarzyna J. Jerzak

rates for 1, 5, and 10 years from the 2019 Canadian Cancer Statistics report, 18 and we used the 15-year net survival rate published by the ACS. 20 The years with unknown age-standardized net survival rates were interpolated by fitting a third

Full access

Neoadjuvant or Adjuvant Chemotherapy Plus Concurrent CRT Versus Concurrent CRT Alone in the Treatment of Nasopharyngeal Carcinoma: A Study Based on EBV DNA

Li-Ting Liu, Qiu-Yan Chen, Lin-Quan Tang, Shan-Shan Guo, Ling Guo, Hao-Yuan Mo, Yang Li, Qing-Nan Tang, Xue-Song Sun, Yu-Jing Liang, Chong Zhao, Xiang Guo, Chao-Nan Qian, Mu-Sheng Zeng, Jin-Xin Bei, Ming-Huang Hong, Jian-Yong Shao, Ying Sun, Jun Ma, and Hai-Qiang Mai

survival rates, and survival curves were compared using the log-rank test. Hazard ratios (HRs) with 95% CIs were calculated using the Cox proportional hazards model. Univariate and multivariate analyses using Cox proportional hazards models were performed

Full access

Integration of Pediatric Hodgkin Lymphoma Treatment and Late Effects Guidelines: Seeing the Forest Beyond the Trees

Matthew J. Ehrhardt, Jamie E. Flerlage, Saro H. Armenian, Sharon M. Castellino, David C. Hodgson, and Melissa M. Hudson

th century. 2 , 3 Subsequently, the 5-year survival rate for children aged <20 years at diagnosis has steadily improved, now exceeding 95% (Figure 1 ). 1 Despite these successes, survival comes at the cost of increased late morbidity 4 – 7 and

Full access

Comparison of Treatment Strategies for Patients With Clinical Stage T1–3/N2 Lung Cancer

Ya-Fu Cheng, Wei-Heng Hung, Heng-Chung Chen, Ching-Yuan Cheng, Ching-Hsiung Lin, Sheng-Hao Lin, and Bing-Yen Wang

illustrates the 5-year OS rates for T1N2, T2N2, and T3N2 stages (27.7%, 21.8%, 19.9%, respectively; P <.0001). Figure 1. Kaplan-Meier survival curves of different T stages for all patients with N2 lung cancer. Table 2 lists survival rates based on

Full access

Salvage or Adjuvant Radiation Therapy: Counseling Patients on the Benefits

Matthew E. Nielsen, Bruce J. Trock, and Patrick C. Walsh

Table 1 Biochemical Recurrence-Free Survival Rates in Adjuvant Radiotherapy Trials Subgroups based on standard prognostic factors, including PSADT, Gleason score, surgical margin status, and pathologic stage, were evaluated for interactions

Full access

Counterpoint: The Case Against Adjuvant High-Dose Interferon-α for Melanoma Patients

Paul B. Chapman

High dose interferon-α (HD IFN) is approved by the United States Food and Drug Administration for adjuvant treatment of patients with stage III melanoma after complete surgical resection. Despite this, clinicians and patients around the world and in many parts of the US have failed to embrace this treatment option because of the lack of overall survival benefit and minimal other clinical benefits seen in randomized trials, combined with the therapy's substantial toxicity. This article reviews the data from the randomized trials that lead to this conclusion and discuss why arguments often advanced in favor of using HD IFN are not persuasive. New treatment options are needed for adjuvant therapy of melanoma. In the meantime, the data from the randomized trials make it difficult for many clinicians and patients to have enthusiasm for adjuvant HD IFN.

Full access

NCCN Task Force Report: Tyrosine Kinase Inhibitor Therapy Selection in the Management of Patients With Chronic Myelogenous Leukemia

Susan O'Brien, Ellin Berman, Joseph O. Moore, Javier Pinilla-Ibarz, Jerald P. Radich, Paul J. Shami, B. Douglas Smith, David S. Snyder, Hema M. Sundar, Moshe Talpaz, and Meir Wetzler

-dose imatinib can experience superior cytogenetic and molecular responses compared with those who need dose reductions. The estimated progression-free survival rates at 18 months for 800 and 400 mg were 97% and 95%, respectively. No significant difference in

Full access

Emerging Therapeutic Options in Acute Lymphoblastic Leukemia

Presented by: Patrick A. Brown

response rates, with complete remission and MRD-negative complete remission between 80% and 90%. 3 Figure 2. Response and survival rates in R/R B-ALL. Abbreviations: B-ALL, B-cell acute lymphoblastic leukemia; BiTE, bispecific T-cell engager; CR, complete

Full access

How NCCN Guidelines Can Help Young Adults and Older Adolescents With Cancer and the Professionals Who Care for Them

Archie Bleyer

Estimated New Cases of and Deaths From Invasive Cancer and Acute Lymphoblastic Leukemia in Adolescents and Young Adults Aged 15–39 Years in the United States, 2009 Figure 1 shows the increase in the 5-year relative survival rate in the United States

Full access

Thymomas and Thymic Carcinomas

David S. Ettinger, Gregory J. Riely, Wallace Akerley, Hossein Borghaei, Andrew C. Chang, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D’Amico, Todd L. Demmy, Ramaswamy Govindan, Frederic W. Grannis Jr, Stefan C. Grant, Leora Horn, Thierry M. Jahan, Ritsuko Komaki, Feng-Ming (Spring) Kong, Mark G. Kris, Lee M. Krug, Rudy P. Lackner, Inga T. Lennes, Billy W. Loo Jr, Renato Martins, Gregory A. Otterson, Jyoti D. Patel, Mary C. Pinder-Schenck, Katherine M. Pisters, Karen Reckamp, Eric Rohren, Theresa A. Shapiro, Scott J. Swanson, Kurt Tauer, Douglas E. Wood, Stephen C. Yang, Kristina Gregory, and Miranda Hughes

are much less invasive than thymic carcinomas. 1 Patients with thymomas have 5-year survival rates of approximately 78%. 4 However, 5-year survival rates for thymic carcinomas are only approximately 40%. 5 , 6 These guidelines outline the evaluation